Literature DB >> 17346167

Designing recombinant vaccines with viral properties: a rational approach to more effective vaccines.

Gary T Jennings1, Martin F Bachmann.   

Abstract

One of the great demands and challenges for vaccination is to successfully target the pathogens responsible for much of mankind's chronic disease burden including: AIDS, infectious hepatitis, tuberculosis and malaria. Another is realizing the potential of therapeutic immunization to cure diseases such as cancer, allergy and inflammatory autoimmunity. To achieve these objectives, the fundamental insights gained from immunology, genomics, molecular-cellular biology and vaccinology must be implemented in order to develop more effective, better defined and safer vaccines. As an illustrative example of this we examine the key features of viruses that are known to be responsible for eliciting superb host immune responses. These insights have formed a basis for understanding the effectiveness of existing vaccines and provide a framework for designing and developing new vaccines better able to meet pressing unmet medical needs. The key immunogenic properties of viruses that are understood to date and are currently being applied include: their particulate nature, their highly repetitive and ordered structures, their ability to induce innate immunity with consequent conditioning of adaptive responses and the kinetics and distribution of viral antigens during infection. Vaccines and vaccine-formulations recently registered for use in humans already incorporate some of these elements. Of great anticipation is the progress of the next-generation vaccines now advancing through the various stages of research and development. Vaccines which, by way of rational design, incorporate viral properties to induce tailored responses and thus have the potential to provide safer and more effective prophylaxis and therapies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17346167     DOI: 10.2174/156652407780059140

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  24 in total

Review 1.  Toll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responses.

Authors:  Egest J Pone; Hong Zan; Jingsong Zhang; Ahmed Al-Qahtani; Zhenming Xu; Paolo Casali
Journal:  Crit Rev Immunol       Date:  2010       Impact factor: 2.214

Review 2.  Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns.

Authors:  Martin F Bachmann; Gary T Jennings
Journal:  Nat Rev Immunol       Date:  2010-10-15       Impact factor: 53.106

3.  Murine immune responses to virus-like particle-associated pre- and postfusion forms of the respiratory syncytial virus F protein.

Authors:  Lori McGinnes Cullen; Madelyn R Schmidt; Sarah A Kenward; Robert T Woodland; Trudy G Morrison
Journal:  J Virol       Date:  2015-04-22       Impact factor: 5.103

Review 4.  Translational Mini-Review Series on Vaccines for HIV: Harnessing innate immunity for HIV vaccine development.

Authors:  E G Rhee; D H Barouch
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

5.  Viral nanoparticles as macromolecular devices for new therapeutic and pharmaceutical approaches.

Authors:  Simone Grasso; Luca Santi
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2010-07-06

Review 6.  Therapeutic vaccines for chronic diseases: successes and technical challenges.

Authors:  Martin F Bachmann; Gary T Jennings
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-10-12       Impact factor: 6.237

7.  Tobacco mosaic virus as a new carrier for tumor associated carbohydrate antigens.

Authors:  Zhaojun Yin; Huong Giang Nguyen; Sudipa Chowdhury; Philip Bentley; Michael A Bruckman; Adeline Miermont; Jeffrey C Gildersleeve; Qian Wang; Xuefei Huang
Journal:  Bioconjug Chem       Date:  2012-08-02       Impact factor: 4.774

8.  Linkage between Anaplasma marginale outer membrane proteins enhances immunogenicity but is not required for protection from challenge.

Authors:  Susan M Noh; Joshua E Turse; Wendy C Brown; Junzo Norimine; Guy H Palmer
Journal:  Clin Vaccine Immunol       Date:  2013-02-27

Review 9.  Severe sepsis and Toll-like receptors.

Authors:  Hongmei Gao; Susannah K Leaver; Anne Burke-Gaffney; Simon J Finney
Journal:  Semin Immunopathol       Date:  2007-12-11       Impact factor: 9.623

10.  Virus-like display of a neo-self antigen reverses B cell anergy in a B cell receptor transgenic mouse model.

Authors:  Bryce Chackerian; Marisa R Durfee; John T Schiller
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.